Literature DB >> 8923482

Increased acetylcholinesterase activity in selected regions of rat brain after chronic (-)-deprenyl administration.

M K Lakshmana1, S Jagadeesh, M N Subhash.   

Abstract

(-)-Deprenyl, 0.05, 1.0, 2.0, and 10.0 mg/kg body weight, was administered intraperitonially to Wistar rats for 30 days. The activity of acetylcholinesterase, and monoamine oxidase A and B were assayed in different brain regions. After the experimental period acetyl cholinesterase activity was found to be significantly increased in frontal cortex [P < 0.001] and hippocampus [P < 0.001] but not in striatum and brainstem at 0.1, 1.0, and 2.0 mg/kg dose, the maximum increase being at 0.1 mg/kg dose. Monoamine oxidase B activity was inhibited by more than 90% at 1.0, 2.0, and 10.0 mg/kg dose while 0.05 and 0.1 dose inhibited only about 55% and 70% respectively. Monoamine oxidase A activity was inhibited to more than 70% at 1.0 mg dose and to more than 90% at 2.0 and 10.0 mg/kg dose. At 0.05 and 0.1 mg/kg dose monoamine oxidase A activity was not significantly altered.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8923482     DOI: 10.1007/bf02532397

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  20 in total

1.  Neuropsychological effects of L-deprenyl in Alzheimer's type dementia.

Authors:  G L Piccinin; G Finali; M Piccirilli
Journal:  Clin Neuropharmacol       Date:  1990-04       Impact factor: 1.592

2.  Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B.

Authors:  K T Finnegan; J J Skratt; I Irwin; L E DeLanney; J W Langston
Journal:  Eur J Pharmacol       Date:  1990-08-02       Impact factor: 4.432

3.  The effect of selective MAO inhibitors on the conditioned avoidance response of Wistar rats.

Authors:  B Knoll; G Held; Z Gyarmati
Journal:  Pol J Pharmacol Pharm       Date:  1977 May-Jun

4.  Sexually low performing male rats die earlier than their high performing peers and (-)deprenyl treatment eliminates this difference.

Authors:  J Knoll; T T Yen; I Miklya
Journal:  Life Sci       Date:  1994       Impact factor: 5.037

5.  Cognitive effects of L-deprenyl in Alzheimer's disease.

Authors:  P N Tariot; T Sunderland; H Weingartner; D L Murphy; J A Welkowitz; K Thompson; R M Cohen
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

6.  Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.

Authors:  G Cohen; M B Spina
Journal:  Ann Neurol       Date:  1989-11       Impact factor: 10.422

7.  The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl.

Authors:  J Knoll
Journal:  Mech Ageing Dev       Date:  1988-12       Impact factor: 5.432

8.  A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl. A selective monoamine oxidase inhibitor.

Authors:  J J Mann; S F Aarons; P J Wilner; J G Keilp; J A Sweeney; T Pearlstein; A J Frances; J H Kocsis; R P Brown
Journal:  Arch Gen Psychiatry       Date:  1989-01

9.  Comparative distribution of dopamine D-1 and D-2 receptors in the basal ganglia of turtles, pigeons, rats, cats, and monkeys.

Authors:  E K Richfield; A B Young; J B Penney
Journal:  J Comp Neurol       Date:  1987-08-15       Impact factor: 3.215

Review 10.  Molecular biology of the amyloid of Alzheimer's disease. An overview.

Authors:  N C Inestrosa; C Soto
Journal:  Biol Res       Date:  1992       Impact factor: 5.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.